London Stock Exchange welcomes Arecor to AIM

London Stock Exchange today welcomes Arecor Therapeutics (“Arecor”) as it begins trading on AIM under the ticker “AREC” having successfully raised £20 million in an oversubscribed raise, giving a market capitalisation at IPO of £62.5 million.

Arecor is a globally focused biopharmaceutical company that is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products.  By applying its innovative proprietary formulation technology platform, Arestat™, Arecor is developing a portfolio of proprietary products and working with leading pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies, supported by an extensive patent portfolio.

The Arestat™ technology, in combination with the extensive know-how of stability requirements, development processes and regulatory requirements, offers a series of formulation options that have been specifically designed to overcome the challenges associated with delivering enhanced pharmaceutical products via reformulation. 

Arecor proprietary product portfolio is currently focused on diabetes and specialty hospital care. For partners, it develops novel enhanced formulations of their biological products that include biosimilars, biological products and vaccines. 

The proceeds will be used to progress the Company’s lead diabetes products, develop and expand its pipeline of specialty hospital Ready-To-Use and Ready-To-Administer products and build the team, as well as bolster working capital and strengthen the balance sheet.

Sarah Howell, Chief Executive Officer of Arecor, said: “Today represents an important milestone for Arecor and we are delighted to be listing on AIM.  This IPO will allow us to continue to grow the business through the development of our own proprietary diabetes and specialty hospital products whilst creating further value through our technology licensing partnerships. We were delighted by the support and interest we received during this transaction which is testament to the potential of our innovative proprietary formulation technology platform, Arestat™. I would like to take this opportunity to thank our new and existing shareholders for their support and we are looking forward to embarking on this next exciting chapter in the Company’s development.”

Andrew Richards, Chairman of Arecor, commented: “Arecor’s technology and expertise has been validated through multiple partnerships with major pharmaceutical and biotechnology companies. The Company also has a balanced business model that offers the potential for significant returns associated with successful drug development but with reduced development risk through development of existing approved therapeutics products and partnering. As someone who has always championed the London market and has supported UK life-science companies to IPO in London I am very pleased Arecor has chosen to list on AIM. Led by a strong team and Board, Arecor has the potential to become a significant UK biopharmaceutical company and deliver benefits to patients and clinicians.” 

Advisers to the IPO: 

Panmure Gordon (UK) Limited, Nominated Advisor and Sole Broker to the Company 
Covington & Burling LLP, Legal Advisers
Grant Thornton, Reporting Accountant
Consilium Communications, Financial PR Advisers

Quick facts

Track
Market: AIM
Instrument market cap (£m)
66.44
Listing/Admission to trading
03 Jun 2021
Looking for new and recent issues?

More recent

106.12
London Stock Exchange welcomes Ecobank Transnational Incorporated’s debut Sustainable Bond to the Sustainable Bond Market

Ecobank Transnational Incorporated (ETI), the parent company of the Ecobank Group, today opened the market at London Stock Exchange via a virtual ceremony to mark the listing of its $350 million 10NC5 Tier 2 Sustainability Notes issuance.

Through its affiliates across 33 sub-Saharan African countries and its international bank in Paris, Ecobank provides the full suite of banking produ

Learn more
108.6
London Stock Exchange welcomes Victorian Plumbing Group plc to AIM

London Stock Exchange today welcomes Victorian Plumbing Group plc (Group or Company), the UK’s leading online retailer of bathroom products and accessories , to AIM under the ticker “VIC”.
 
Headquartered in Skelmersdale, Lancashire, the Group employs over 500 colleagues across seven locations in Skelmersdale, Manchester and Birmingham.
 
Victorian Plumbing

Learn more
London Stock Exchange welcomes Spectral MD Holdings, Ltd. to AIM

London Stock Exchange today welcomes Spectral MD Holdings, Ltd. (“Spectral MD” of the “Company”) (AIM: SMD) a predictive analytics group that develops proprietary AI algorithms and optical technology for faster treatment decisions in wound care, headquartered in Dallas, Texas, U.S.A. 

Using its DeepView® Wound Imaging Solution, an internally developed AI technology and multispect

Learn more
119.28
London Stock Exchange welcomes Thor Explorations to AIM

London Stock Exchange welcomes Thor Explorations, a West African focussed gold company to AIM under the ticker “THX”. The Company will be trading its common shares and has a market capitalization of circa. £135 million at admission. The listing is supplementary to the Company's listing on the TSX-V in Canada. 

Thor Explorations, which will shortly commence gold production at

Learn more